Current Opinion in Lipidology
Journal Impact IF - Analysis · Trend · Prediction · Ranking


New

Journal Impact IF

2019-2020

4.254

-12.2 %

Journal Impact IF Trend

Related Journals

Popular Journals

Current Opinion in Lipidology

The 2019-2020 Journal Impact IF of Current Opinion in Lipidology is 4.254, which is just updated in 2020.

Current Opinion in Lipidology Impact Factor
Highest IF
6.086
Highest Journal Impact IF

The highest Journal Impact IF of Current Opinion in Lipidology is 6.086.

Lowest IF
3.853
Lowest Journal Impact IF

The lowest Journal Impact IF of Current Opinion in Lipidology is 3.853.

Total Growth Rate
-30.1%
IF Total Growth Rate

The total growth rate of Current Opinion in Lipidology IF is -30.1%.

Annual Growth Rate
-3.3%
IF Annual Growth Rate

The annual growth rate of Current Opinion in Lipidology IF is -3.3%.

Journal Impact IF Ranking

Subcategory Quartile Rank Percentile
Genetics Q1 56/324

Genetics 82%

Cell Biology Q1 62/274

Cell Biology 77%

Cardiology and Cardiovascular Medicine Q1 41/324

Cardiology and Cardiovascular Medicine 87%

Molecular Biology Q1 85/381

Molecular Biology 77%

Nutrition and Dietetics Q1 15/120

Nutrition and Dietetics 87%

Endocrinology, Diabetes and Metabolism Q1 32/217

Endocrinology, Diabetes and Metabolism 85%

Journal Impact IF Ranking

· In the Genetics research field, the Quartile of Current Opinion in Lipidology is Q1. Current Opinion in Lipidology has been ranked #56 over 324 related journals in the Genetics research category. The ranking percentile of Current Opinion in Lipidology is around 82% in the field of Genetics.
· In the Cell Biology research field, the Quartile of Current Opinion in Lipidology is Q1. Current Opinion in Lipidology has been ranked #62 over 274 related journals in the Cell Biology research category. The ranking percentile of Current Opinion in Lipidology is around 77% in the field of Cell Biology.
· In the Cardiology and Cardiovascular Medicine research field, the Quartile of Current Opinion in Lipidology is Q1. Current Opinion in Lipidology has been ranked #41 over 324 related journals in the Cardiology and Cardiovascular Medicine research category. The ranking percentile of Current Opinion in Lipidology is around 87% in the field of Cardiology and Cardiovascular Medicine.
· In the Molecular Biology research field, the Quartile of Current Opinion in Lipidology is Q1. Current Opinion in Lipidology has been ranked #85 over 381 related journals in the Molecular Biology research category. The ranking percentile of Current Opinion in Lipidology is around 77% in the field of Molecular Biology.
· In the Nutrition and Dietetics research field, the Quartile of Current Opinion in Lipidology is Q1. Current Opinion in Lipidology has been ranked #15 over 120 related journals in the Nutrition and Dietetics research category. The ranking percentile of Current Opinion in Lipidology is around 87% in the field of Nutrition and Dietetics.
· In the Endocrinology, Diabetes and Metabolism research field, the Quartile of Current Opinion in Lipidology is Q1. Current Opinion in Lipidology has been ranked #32 over 217 related journals in the Endocrinology, Diabetes and Metabolism research category. The ranking percentile of Current Opinion in Lipidology is around 85% in the field of Endocrinology, Diabetes and Metabolism.

Current Opinion in Lipidology Impact Factor 2020-2021 Prediction

Current Opinion in Lipidology Impact Factor Predition System

Current Opinion in Lipidology Impact Factor Prediction System is now online. You can start share your valuable insights with the community.

Predict Check All Preditions
Total Publications
2511
Total Citations
130930

Annual Publication Volume

Annual Citation Record

International Collaboration Trend

Cited Documents Trend

Journal Impact IF History

Year Journal Impact IF
Year Journal Impact IF
2019-2020 4.254
2018-2019 4.844
2017-2018 3.853
2016-2017 4.096
2015-2016 5.336
2014-2015 5.656
2013-2014 5.803
2012-2013 5.839
2011-2012 6.086
Journal Impact IF History

· The 2019-2020 Journal Impact IF of Current Opinion in Lipidology is 4.254
· The 2018-2019 Journal Impact IF of Current Opinion in Lipidology is 4.844
· The 2017-2018 Journal Impact IF of Current Opinion in Lipidology is 3.853
· The 2016-2017 Journal Impact IF of Current Opinion in Lipidology is 4.096
· The 2015-2016 Journal Impact IF of Current Opinion in Lipidology is 5.336
· The 2014-2015 Journal Impact IF of Current Opinion in Lipidology is 5.656
· The 2013-2014 Journal Impact IF of Current Opinion in Lipidology is 5.803
· The 2012-2013 Journal Impact IF of Current Opinion in Lipidology is 5.839
· The 2011-2012 Journal Impact IF of Current Opinion in Lipidology is 6.086

Publications Cites Dataset

Year Publications Citations
Year Publications Citations
1983 1 2
1984 0 2
1985 0 5
1986 0 3
1987 0 5
1988 0 3
1989 0 5
1990 74 25
1991 66 41
1992 64 152
1993 79 384
1994 80 532
1995 79 851
1996 81 1250
1997 77 1439
1998 65 1996
1999 65 2593
2000 74 3213
2001 71 3670
2002 75 4251
2003 74 4388
2004 86 4727
2005 68 4891
2006 107 5471
2007 117 5683
2008 122 6050
2009 86 6317
2010 85 6960
2011 77 6927
2012 85 7555
2013 81 7869
2014 77 7506
2015 90 7295
2016 108 6247
2017 77 5816
2018 78 4789
2019 75 5314
2020 57 6229
2021 10 474
Publications Cites Dataset

· The Current Opinion in Lipidology has published 1 reports and received 2 citations in 1983.
· The Current Opinion in Lipidology has published 0 reports and received 2 citations in 1984.
· The Current Opinion in Lipidology has published 0 reports and received 5 citations in 1985.
· The Current Opinion in Lipidology has published 0 reports and received 3 citations in 1986.
· The Current Opinion in Lipidology has published 0 reports and received 5 citations in 1987.
· The Current Opinion in Lipidology has published 0 reports and received 3 citations in 1988.
· The Current Opinion in Lipidology has published 0 reports and received 5 citations in 1989.
· The Current Opinion in Lipidology has published 74 reports and received 25 citations in 1990.
· The Current Opinion in Lipidology has published 66 reports and received 41 citations in 1991.
· The Current Opinion in Lipidology has published 64 reports and received 152 citations in 1992.
· The Current Opinion in Lipidology has published 79 reports and received 384 citations in 1993.
· The Current Opinion in Lipidology has published 80 reports and received 532 citations in 1994.
· The Current Opinion in Lipidology has published 79 reports and received 851 citations in 1995.
· The Current Opinion in Lipidology has published 81 reports and received 1250 citations in 1996.
· The Current Opinion in Lipidology has published 77 reports and received 1439 citations in 1997.
· The Current Opinion in Lipidology has published 65 reports and received 1996 citations in 1998.
· The Current Opinion in Lipidology has published 65 reports and received 2593 citations in 1999.
· The Current Opinion in Lipidology has published 74 reports and received 3213 citations in 2000.
· The Current Opinion in Lipidology has published 71 reports and received 3670 citations in 2001.
· The Current Opinion in Lipidology has published 75 reports and received 4251 citations in 2002.
· The Current Opinion in Lipidology has published 74 reports and received 4388 citations in 2003.
· The Current Opinion in Lipidology has published 86 reports and received 4727 citations in 2004.
· The Current Opinion in Lipidology has published 68 reports and received 4891 citations in 2005.
· The Current Opinion in Lipidology has published 107 reports and received 5471 citations in 2006.
· The Current Opinion in Lipidology has published 117 reports and received 5683 citations in 2007.
· The Current Opinion in Lipidology has published 122 reports and received 6050 citations in 2008.
· The Current Opinion in Lipidology has published 86 reports and received 6317 citations in 2009.
· The Current Opinion in Lipidology has published 85 reports and received 6960 citations in 2010.
· The Current Opinion in Lipidology has published 77 reports and received 6927 citations in 2011.
· The Current Opinion in Lipidology has published 85 reports and received 7555 citations in 2012.
· The Current Opinion in Lipidology has published 81 reports and received 7869 citations in 2013.
· The Current Opinion in Lipidology has published 77 reports and received 7506 citations in 2014.
· The Current Opinion in Lipidology has published 90 reports and received 7295 citations in 2015.
· The Current Opinion in Lipidology has published 108 reports and received 6247 citations in 2016.
· The Current Opinion in Lipidology has published 77 reports and received 5816 citations in 2017.
· The Current Opinion in Lipidology has published 78 reports and received 4789 citations in 2018.
· The Current Opinion in Lipidology has published 75 reports and received 5314 citations in 2019.
· The Current Opinion in Lipidology has published 57 reports and received 6229 citations in 2020.
· The Current Opinion in Lipidology has published 10 reports and received 474 citations in 2021.
· The total publications of Current Opinion in Lipidology is 2511.
· The total citations of Current Opinion in Lipidology is 130930.

What is Impact Factor?

The impact factor (IF) or journal impact factor (JIF) of an academic journal is a scientometric index calculated by Clarivate that reflects the yearly average number of citations of articles published in the last two years in a given journal. It is frequently used as a proxy for the relative importance of a journal within its field; journals with higher impact factor values are often deemed to be more important, or carry more intrinsic prestige in their respective fields, than those with lower values.

Current Opinion in Lipidology | Academic Accelerator - About the Impact Factor

Impact factor is commonly used to evaluate the relative importance of a journal within its field and to measure the frequency with which the “average article” in a journal has been cited in a particular time period. Journal which publishes more review articles will get highest IFs. Journals with higher IFs believed to be more important than those with lower ones. According to Eugene Garfield “impact simply reflects the ability of the journals and editors to attract the best paper available.” Journal which publishes more review articles will get maximum IFs. The Impact Factor of an academic journal is a scientometric Metric that reflects the yearly average number of citations that recent articles published in a given journal received. It is frequently used as a Metric for the relative importance of a journal within its field; journals with higher Impact Factor are often deemed to be more important than those with lower ones. The Current Opinion in Lipidology Impact Factor IF measures the average number of citations received in a particular year (2020) by papers published in the Current Opinion in Lipidology during the two preceding years (2018-2019). Note that 2020 Impact Factor are reported in 2021; they cannot be calculated until all of the 2020 publications have been processed by the indexing agency. New journals, which are indexed from their first published issue, will receive an impact factor after two years of indexing; in this case, the citations to the year prior to Volume 1, and the number of articles published in the year prior to Volume 1, are known zero values. Journals that are indexed starting with a volume other than the first volume will not get an impact factor until they have been indexed for three years. Occasionally, Journal Citation Reports assigns an impact factor to new journals with less than two years of indexing, based on partial citation data. The calculation always uses two complete and known years of item counts, but for new titles one of the known counts is zero. Annuals and other irregular publications sometimes publish no items in a particular year, affecting the count. The impact factor relates to a specific time period; it is possible to calculate it for any desired period. In addition to the 2-year Impact Factor, the 3-year Impact Factor, 4-year Impact Factor, 5-year Impact Factor, Real-Time Impact Factor can provide further insights and factors into the impact of Current Opinion in Lipidology.

History

The impact factor was devised by Eugene Garfield, the founder of the Institute for Scientific Information (ISI). Impact factors are calculated yearly starting from 1975 for journals listed in the Journal Citation Reports (JCR). ISI was acquired by Thomson Scientific & Healthcare in 1992, and became known as Thomson ISI. In 2018, Thomson ISI was sold to Onex Corporation and Baring Private Equity Asia. They founded a new corporation, Clarivate, which is now the publisher of the JCR.

Use

The impact factor is used to compare different journals within a certain field. The Web of Science indexes more than 11,500 science and social science journals. Journal impact factors are often used to evaluate the merit of individual articles and individual researchers. This use of impact factors was summarised by Hoeffel:

Impact Factor is not a perfect tool to measure the quality of articles but there is nothing better and it has the advantage of already being in existence and is, therefore, a good technique for scientific evaluation. Experience has shown that in each specialty the best journals are those in which it is most difficult to have an article accepted, and these are the journals that have a high impact factor. Most of these journals existed long before the impact factor was devised. The use of impact factor as a measure of quality is widespread because it fits well with the opinion we have in each field of the best journals in our specialty....In conclusion, prestigious journals publish papers of high level. Therefore, their impact factor is high, and not the contrary.

Eugene Garfield

In brief, Impact factors may be used by:
  • Authors to decide where to submit an article for publication.
  • Libraries to make collection development decisions
  • Academic departments to assess academic productivity
  • Academic departments to make decisions on promotion and tenure.
As impact factors are a journal-level metric, rather than an article- or individual-level metric, this use is controversial. Garfield agrees with Hoeffel,but warns about the "misuse in evaluating individuals" because there is "a wide variation [of citations] from article to article within a single journal". Other things to consider about Impact Factors:
  • Many journals do not have an impact factor.
  • The impact factor cannot assess the quality of individual articles. Even if citations were evenly distributed among articles, the impact factor would only measure the interests of other researchers in an article, not its importance and usefulness.
  • Only research articles, technical notes and reviews are “citable” items. Editorials, letters, news items and meeting abstracts are “non-citable items”.
  • Only a small percentage of articles are highly cited and they are found in a small subset of journals. This small proportion accounts for a large percentage of citations.
  • Controversial papers, such as those based on fraudulent data, may be highly cited, distorting the impact factor of a journal.
  • Citation bias may exist. For example, English language resources may be favoured. Authors may cite their own work.
Moreover, informed and careful use of these impact data is essential, and should be based on a thorough understanding of the methodology used to generate impact factors. There are controversial aspects of using impact factors:
  • It is not clear whether the number of times a paper is cited measures its actual quality.
  • Some databases that calculate impact factors fail to incorporate publications including textbooks, handbooks and reference books.
  • Certain disciplines have low numbers of journals and usage. Therefore, one should only compare journals or researchers within the same discipline.
  • Review articles normally are cited more often and therefore can skew results.
  • Self-citing may also skew results.
  • Some resources used to calculate impact factors have inadequate international coverage.
  • Editorial policies can artificially inflate an impact factor.
Impact factors have often been used in advancement and tenure decision-making. Many recognize that this is a coarse tool for such important decisions, and that a multitude of factors should be taken into account in these deliberations. When considering the use of the impact factor (IF), keep these aspects in mind:
  • IF analysis is limited to citations from the journals indexed by the Web of Science/Web of Knowledge. Currently, the Web of Science indexes only 8621 journals across the full breadth of the sciences, and just 3121 in the social sciences.
  • A high IF/citation rate says nothing about the quality -- or even, validity -- of the references being cited. Notorious or even retracted articles often attract a lot of attention, hence a high number of citations. The notority related to the first publication on "cold fusion" is one such example.
  • Journals that publish more "review articles" are often found near the top of the rankings. While not known for publishing new, creative findings, these individual articles tend to be heavily cited.
  • The IF measures the average number of citations to articles in the journal -- given this, a small number of highly-cited articles will skew the figure.
  • It takes several years for new journals to be added to the list of titles indexed by the Web of Science/Web of Knowledge, so these newer titles will be under-represented.
  • It's alleged that journal editors have learned to "game" the system, encouraging authors to cite their works previously published in the same journal.
Comparing Journals Across Disciplines? Not a good idea! Using Impact Factors within a given discipline should only be done with great care, as described above. Using impact factor data to compare journals across disciplines is even more problematic. Here are some of the reasons:
  • Disciplines where older literature is still referenced, such as Chemistry and Mathematics, offer challenges to the methodolgy since older citations (older than two years) are not used to calculate the impact factor for a given journal. (Five-year impact factor analysis, which can be calculated using the Journal Citation Index database, helps smooth out this problem only to some degree.)
  • Different disciplines have different practices regarding tendency to cite larger numbers of references. Higher overall citation rates will bump upward impact factor measurements.
  • Where it's common for large numbers of authors to collaborate on a single paper, such as in Physics, the tendency of authors to cite themselves (and in this case, more authors) will result in increased citation rates.

Pros and Cons of the Impact Factor

Pros:

  • A vetted, established metric for measuring journal impact within a discipline.
  • Designed to eliminate bias based on journal size and frequency.
Cons:
  • Individual articles makes an uneven contribution to overall Impact Factor.
  • Impact Factor does not account for certain things, things like context (postive or negative citaion) and intentionality (self-citation).
  • The metric is proprietary to and bound by the contents of the Thomson Reuters database.
  • Citations, on which the Impact Factor is based, count for less than 1% of an article's overall use.

Criticism

Numerous critiques have been made regarding the use of impact factors. A 2007 study noted that the most fundamental flaw is that impact factors present the mean of data that are not normally distributed, and suggested that it would be more appropriate to present the median of these data. There is also a more general debate on the validity of the impact factor as a measure of journal importance and the effect of policies that editors may adopt to boost their impact factor (perhaps to the detriment of readers and writers). Other criticism focuses on the effect of the impact factor on behavior of scholars, editors and other stakeholders. Others have made more general criticisms, arguing that emphasis on impact factor results from negative influence of neoliberal policies on academia claiming that what is needed is not just replacement of the impact factor with more sophisticated metrics for science publications but also discussion on the social value of research assessment and the growing precariousness of scientific careers in higher education.
Experts stress that there are limitations in using impact factors to evaluate a scholar's work. There are many reasons cited for not relying on impact factor alone to evaluate the output of a particular individual. Among these are the following:

  • A single factor is not sufficient for evaluating an author's work.
  • Journal values are meaningless unless compared within the same discipline. Impact factors vary among disciplines.
  • The impact factor was originally devised to show the impact of a specific journal, not a specific scholar. The quality and impact of the author's work may extend beyond the impact of a particular journal.
According to Jim Testa, a researcher for ThomsonReuters Scientific, the most widespread misuse of the Impact Factor is to evaluate the work of an individual author (instead of a journal). "To say that because a researcher is publishing in a certain journal, he or she is more influential or deserves more credit is not necessarily true. There are many other variables to consider." (interview 6/26/2008 in Thomson Reuters blog entry)

Current Opinion in Lipidology
Journal Profile

About

With its easy-to-digest reviews on important advances in world literature, Current Opinion in Lipidology offers expert evaluation on a wide range of topics from six key disciplines including nutrition and metabolism, genetics and molecular biology, and hyperlipidaemia and cardiovascular disease. Published bimonthly, each issue covers in detail the most pertinent advances in these fields from the previous year. This is supplemented by a section of Bimonthly Updates, which deliver an insight into new developments at the cutting edge of the disciplines covered in the journal. None

Highly Cited Keywords

ISSN
0957-9672
ISSN

The ISSN of Current Opinion in Lipidology is 0957-9672 . An ISSN is an 8-digit code used to identify newspapers, journals, magazines and periodicals of all kinds and on all media–print and electronic.

ISSN (Online)
1473-6535
ISSN (Online)

The ISSN (Online) of Current Opinion in Lipidology is 1473-6535 . An ISSN is an 8-digit code used to identify newspapers, journals, magazines and periodicals of all kinds and on all media–print and electronic.

Publisher
Lippincott Williams and Wilkins Ltd.
Publisher

Current Opinion in Lipidology is published by Lippincott Williams and Wilkins Ltd. .

Publication Frequency
Bimonthly
Publication Frequency

Current Opinion in Lipidology publishes reports Bimonthly .

Coverage
1990 - Present
Coverage

The Publication History of Current Opinion in Lipidology covers 1990 - Present .

Open Access
NO
Open Access

Current Opinion in Lipidology is Subscription-based (non-OA) Journal. Publishers own the rights to the articles in their journals. Anyone who wants to read the articles should pay by individual or institution to access the articles. Anyone who wants to use the articles in any way must obtain permission from the publishers.

Publication Fee
Publication Fee

There is no publication fee for submiting manuscript to Current Opinion in Lipidology. Current Opinion in Lipidology is Subscription-based (non-OA) Journal. Publishers own the rights to the articles in their journals. Anyone who wants to read the articles should pay by individual or institution to access the articles.

Language
English
Language

The language of Current Opinion in Lipidology is English .

Country/Region
United States
Country/Region

The publisher of Current Opinion in Lipidology is Lippincott Williams and Wilkins Ltd. , which locates in United States .

Selected Articles

Full Title Authors
Full Title Authors
Therapy and clinical trials Stephen J. Nicholls · Rishi Puri · Rishi Puri
Can we still learn from the Seven Countries Study Jillian Davidson · Dino Rotondo · Dino Rotondo
Control of serum triglyceride levels by the apolipoprotein C3 gene and its relationship to cardiovascular disease Martine Paquette · Alexis Baass · Alexis Baass
Predicting cardiovascular disease in familial hypercholesterolemia Katrin Niisuke · Katalin V. Horvath · Bela F. Asztalos · Bela F. Asztalos
Where next with HDL assays Kamal Awad · Maciej Banach · Maciej Banach
Towards more specific treatment for diabetic dyslipidemia Alicia J. Jenkins · Paul Welsh · John R. Petrie · John R. Petrie
Metformin, lipids and atherosclerosis prevention Marjolein A.W. van den Boogert · Daniel J. Rader · Adriaan G. Holleboom · Adriaan G. Holleboom
Transintestinal cholesterol excretion in humans Kazuhiro Nakaya · Katsunori Ikewaki · Katsunori Ikewaki
PURE and simple? A new perspective on the impact of diet on hyperlipidemia and cardiovascular risk Deepak Bhatnagar · Ahmad Shiraz · Ahmad Shiraz
Microbiota and HDL metabolism Laurence D. Parnell · Jose M. Ordovas · Chao-Qiang Lai · Chao-Qiang Lai
Membrane microdomains and the regulation of HDL biogenesis Natalie C. Ward · Amirhossein Sahebkar · Maciej Banach · Gerald F. Watts · Gerald F. Watts
Control of intestinal lipoprotein secretion by dietary carbohydrates Esben Søndergaard · Søren Nielsen · Søren Nielsen
Cholesterol metabolism in humans: a review of methods and comparison of results Michael A. Iacocca · Robert A. Hegele · Robert A. Hegele
Plasma apolipoprotein-B is an important risk factor for cardiovascular disease, and its assessment should be routine clinical practice Susanne Pfeiler · Susanne Pfeiler
Modulation of cardiovascular risk factors Alessandro Menotti · Paolo Emilio Puddu · Paolo Emilio Puddu
Unexplained reciprocal regulation of diabetes and lipoproteins Uwe J. F. Tietge · Uwe J. F. Tietge
Atherosclerosis: cell biology and lipoproteins – focus on anti-inflammatory therapies Jacqueline S. Dron · Robert A. Hegele · Robert A. Hegele
Familial hypercholesterolemia: experience from the French-Canadian population Amy C. Burke · Murray W. Huff · Murray W. Huff
The lysophosphatidic acid acyltransferases (acylglycerophosphate acyltransferases) family: one reaction, five enzymes, many roles Jean-Pierre Rabès · Sophie Béliard · Alain Carrié · Alain Carrié
Familial hypercholesterolemia: experience from France Erin E. Mulvihill · Erin E. Mulvihill
Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2 Andrea Volta · G. Kees Hovingh · Aldo Grefhorst · Aldo Grefhorst
Genetics of familial hypercholesterolemia: a tool for development of novel lipid lowering pharmaceuticals? Nabil G. Seidah · Michel Chrétien · Majambu Mbikay · Majambu Mbikay
The journey towards understanding lipoprotein(a) and cardiovascular disease risk: are we there yet? Martine Paquette · Jacques Genest · Alexis Baass · Alexis Baass
Regression of atherosclerosis: lessons learned from genetically modified mouse models Coen van Solingen · Kaitlyn R. Scacalossi · Kathryn J. Moore · Kathryn J. Moore
Multifaceted functions of macrophages in atherosclerosis Handrean Soran · Jan Hoong Ho · Paul N. Durrington · Paul N. Durrington
Long noncoding RNAs in lipid metabolism Joerg Heeren · Ludger Scheja · Ludger Scheja
Brown adipose tissue and lipid metabolism Xiangyu Zhang · Trent D. Evans · Se-Jin Jeong · Babak Razani · Babak Razani
Classical and alternative roles for autophagy in lipid metabolism Venetia Bazioti · Anouk M. la Rose · Marit Westerterp · Marit Westerterp
Myeloid cells regulate plasma LDL-cholesterol levels Neale D. Ridgway · Kexin Zhao · Kexin Zhao
Cholesterol transfer at endosomal-organelle membrane contact sites Sheila A. Doggrell · Sheila A. Doggrell
What have we learnt from the clinical outcomes trials with the cetrapibs Alexander N. Orekhov · Alexander N. Orekhov
Role of DNA copy number variation in dyslipidemias Manja Koch · Majken K. Jensen · Majken K. Jensen
Acquired low cholesterol: diagnosis and relevance to safety of low LDL therapeutic targets Sei Higuchi · M. Concepción Izquierdo · Rebecca A. Haeusler · Rebecca A. Haeusler
Body mass index and risk of dementia Lauren Sharan · Richard A. Krasuski · Richard A. Krasuski
Population specific genetic heterogeneity of familial hypercholesterolemia in South Africa Holger Winkels · Erik Ehinger · Yanal Goshesh · Dennis Wolf · Klaus Ley · Klaus Ley
Paths to progress on protective dietary patterns Kia Peters · Rachel Wilson · Nica M. Borradaile · Nica M. Borradaile
Atherosclerosis in the single-cell era Anton Gisterå · Daniel F.J. Ketelhuth · Daniel F.J. Ketelhuth
Lipid-driven immunometabolic responses in atherosclerosis Janine van Duijn · Johan Kuiper · Bram Slütter · Bram Slütter
Metabolism of innate immune cells: impact on atherosclerosis Karthickeyan Chella Krishnan · Margarete Mehrabian · Aldons J. Lusis · Aldons J. Lusis
The many faces of CD8+ T cells in atherosclerosis Pei-Yu Chen · Michael Simons · Michael Simons
Sex differences in metabolism and cardiometabolic disorders Carla Winter · Oliver Soehnlein · Oliver Soehnlein
The potential of chronopharmacology for treatment of atherosclerosis Oren Rom · Luis Villacorta · Jifeng Zhang · Y. Eugene Chen · Michael Aviram · Michael Aviram
Writing on the wall for precision medicine in the prevention of atherosclerotic cardiovascular disease Theodosios D. Filippatos · Eliza C. Christopoulou · Moses Elisaf · Moses Elisaf
New insights in the multiple roles of bile acids and their signaling pathways in metabolic control Natalie Smyth · Michele Ramsay · Frederick J. Raal · Frederick J. Raal
Metabolism: The road to inflammation and atherosclerosis Gerald F. Watts · E.S.G. Stroes · E.S.G. Stroes
Polygenic influences on dyslipidemias Charles Thomas · Louise Ménégaut · David Masson · David Masson
Emerging therapeutic potential of glycine in cardiometabolic diseases: dual benefits in lipid and glucose metabolism Manja Koch · Klodian Dhana · Majken K. Jensen · Majken K. Jensen
Burning fat to keep your stem cells? The role of fatty acid oxidation in various tissue stem cells Buerger F · Burkhardt R · Burkhardt R
Antioxidants and risk of dementia: recent insights and future opportunities Stéphane Ramin-Mangata · Valentin Blanchard · Gilles Lambert · Gilles Lambert
RNA-targeted therapeutics for lipid disorders Kate T. Creasy · John P. Kane · Mary J. Malloy · Mary J. Malloy
Key aspects of PCSK9 inhibition beyond LDL lowering Maaike Kockx · Leonard Kritharides · Leonard Kritharides
The prediction of therapy-benefit for individual cardiovascular disease prevention: rationale, implications, and implementation Lubna Ali · Johan G. Schnitzler · Jeffrey Kroon · Jeffrey Kroon
Stem cell modeling of lipid genetics Dawn C. Schwenke · Dawn C. Schwenke
Intestinal cholesterol absorption Sotirios Tsimikas · Sotirios Tsimikas
Lysosomal acid lipase and lipid metabolism: new mechanisms, new questions, and new therapies Kiran Musunuru · Kiran Musunuru
The role of patient registries for rare genetic lipid disorders Bastian Ramms · Philip L.S.M. Gordts · Philip L.S.M. Gordts
Hand of FATe: lipid metabolism in hematopoietic stem cells Lilli Arndt · Ralph Burkhardt · Ralph Burkhardt
Branched-chain amino acids and atherosclerosis: friends or foes? Kirstin Mittelstraß · Melanie Waldenberger · Melanie Waldenberger
Poststatin era in atherosclerosis management: lessons from epidemiologic and genetic studies Claudia Grajeda-Iglesias · Oren Rom · Michael Aviram · Michael Aviram
Lipid metabolism: spotlight on modulators of lipoprotein lipase activity Jan de Boer · Vincent W. Bloks · Esther Verkade · M Rebecca Heiner-Fokkema · Folkert Kuipers · Folkert Kuipers
DNA methylation in human lipid metabolism and related diseases Hanrui Zhang · Hanrui Zhang
Novel metabolic phenotypes in lecithin cholesterol acyltyransferase-deficient mice Ryan M. Bradley · Robin E. Duncan · Robin E. Duncan
Relevance of human fat distribution on lipid and lipoprotein metabolism and cardiovascular disease risk Peter L. Thompson · S. Mark Nidorf · S. Mark Nidorf
The optimal time of day for statin administration: a review of current evidence Valentina Rodriguez · Jonathan D. Newman · Arthur Schwartzbard · Arthur Schwartzbard
Environmental and epigenetic regulation of postprandial lipemia Priska Stahel · Changting Xiao · Gary F. Lewis · Gary F. Lewis
Vldl triglyceride accumulation in skeletal muscle and adipose tissue in type 2 diabetes Stella Trompet · Chris J. Packard · J. Wouter Jukema · J. Wouter Jukema
The ever-expanding saga of the proprotein convertases and their roles in body homeostasis: emphasis on novel proprotein convertase subtilisin kexin number 9 functions and regulation Michael B. Boffa · Marlys L. Koschinsky · Marlys L. Koschinsky
LDL and foam cell formation as the basis of atherogenesis Chia-Hua Wu · Alan Daugherty · Hong Lu · Hong Lu
Cardiovascular oncology: exploring the effects of targeted cancer therapies on atherosclerosis Marlen Knobloch · Christian Widmann · Christian Widmann
Non-parenchymal hepatic cell lipotoxicity and the coordinated progression of non-alcoholic fatty liver disease and atherosclerosis Niels P. Riksen · Rinke Stienstra · Rinke Stienstra
Fibroblast growth factor–transforming growth factor beta dialogues, endothelial cell to mesenchymal transition, and atherosclerosis Tom Seijkens · Esther Lutgens · Esther Lutgens
Emerging roles of HDL in immune function Marie-Eve Piché · Senthil K. Vasan · Leanne Hodson · Fredrik Karpe · Fredrik Karpe
Atherosclerotic cardiovascular disease risk assessment in familial hypercholesterolemia: does one size fit all? N E M Jaspers · Paul M. Ridker · Jannick A.N. Dorresteijn · Frank L.J. Visseren · Frank L.J. Visseren
Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism Man K.S. Lee · Annas Al-Sharea · Dragana Dragoljevic · Andrew J. Murphy · Andrew J. Murphy
Targeted therapies and outcomes data: the inflammatory hypothesis matures David M. Ng · Amanda J. Hooper · M. Bellgard · John R. Burnett · John R. Burnett
Emerging role of notch 1 signaling in brown adipogenesis Catrin A. Higgins · Alan Rees · Alan Rees
Hyperlipidemia and cardiovascular disease with focus on familial hypercholesterolemia Kim van Kuijk · Andrew H. Baker · Judith C. Sluimer · Judith C. Sluimer
Atherosclerosis development : lipoproteins and beyond Laurens F. Reeskamp · Emma C. E. Meessen · Albert K. Groen · Albert K. Groen
Recent perspectives on the role of nutraceuticals as cholesterol-lowering agents John S. Millar · Marina Cuchel · Marina Cuchel
Fatty acids and macrophage functions: an update Laurent Yvan-Charvet · Bertrand Cariou · Bertrand Cariou
Interpreting lipoproteins in nonalcoholic fatty liver disease Roelof A.J. Smit · J. Wouter Jukema · Stella Trompet · Stella Trompet
Beyond cascade screening: detection of familial hypercholesterolaemia at childhood immunization and other strategies David J. Galton · David J. Galton
Cholesterol: A dark horse in signalling race Dawn C. Schwenke · Dawn C. Schwenke
Genotype-guided diagnosis in familial hypercholesterolemia: population burden and cascade screening Mehdi Afshar · George Thanassoulis · George Thanassoulis
Does lifestyle contribute to disease severity in patients with inherited lipid disorders Paul N. Hopkins · Paul N. Hopkins
News on the molecular regulation and function of hepatic low-density lipoprotein receptor and LDLR-related protein 1 Menno Hoekstra · Mary G. Sorci-Thomas · Mary G. Sorci-Thomas
ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia Raul D. Santos · Raul D. Santos
Serum inhibitory factor 1, high-density lipoprotein and cardiovascular diseases Ángel Baldán · Carlos Fernández-Hernando · Carlos Fernández-Hernando
Optimizing dietary patterns to decrease premature mortality C. Roger White · G. M. Anantharamaiah · G. M. Anantharamaiah
The shape of things to come in lipid management: a feast of reason Mathew Traini · Leonard Kritharides · Leonard Kritharides
LDL particle number and size and cardiovascular risk: anything new under the sun? Katriina Nemes · Fredrik Åberg · Fredrik Åberg
Gene therapy, a promising treatment for familial hypercholesterolaemia Sebastiano Calandra · Patrizia Tarugi · Stefano Bertolini · Stefano Bertolini
New insights into the role of glycosylation in lipoprotein metabolism Klaus G. Parhofer · Klaus G. Parhofer
New approaches to address dyslipidemia Angela Pirillo · Giuseppe Danilo Norata · Giuseppe Danilo Norata · Alberico L. Catapano · Alberico L. Catapano
Strategies for the use of nonstatin therapies Klaus G. Parhofer · Klaus G. Parhofer
Implications of GLAGOV study Anthony Keech · Alicia J. Jenkins · Alicia J. Jenkins
Triglyceride-lowering trials Gerald F. Watts · Erik S.G. Stroes · Erik S.G. Stroes
Lipids grease the wheels of the immune system Peter M. Clifton · Jennifer B. Keogh · Jennifer B. Keogh
Increasing HDL-C levels with medication: current perspectives Andrew C. R. Martin · Damon A. Bell · Tom Brett · Gerald F. Watts · Gerald F. Watts
Role of dietary advanced glycation end products John P. Kane · Ernst J. Schaefer · Mary J. Malloy · Mary J. Malloy
Xenosterolemia: emerging molecular and clinical insights Raul D. Santos · Raul D. Santos
Genetics and molecular biology controversies on Mendelian randomization and proprotein convertase subtilisin–kexin type 9 inhibitor clinical trials: more data still necessary Kirsten B. Holven · Stine M. Ulven · Martin P. Bogsrud · Martin P. Bogsrud
Novel lipid modifying drugs to lower LDL cholesterol Feiming Ye · Wang J · Alan Daugherty · Hong Lu · Hong Lu
Autophagy and hepatic steatosis Dimitri Sviridov · Nigora Mukhamedova · Nigora Mukhamedova
Membrane lipids and cell signaling Giuseppe Ciccarella · Gertrud Lund · Silvio Zaina · Silvio Zaina
Protein changes in non-LDL-lipoproteins in familial hypercholesterolemia: implications in cardiovascular disease manifestation and outcome Hannah Sunshine · Maria Luisa Iruela-Arispe · Maria Luisa Iruela-Arispe
Mechanisms of erosion of atherosclerotic plaques Lina Badimon · Teresa Padró · Judit Cubedo · Judit Cubedo
Lipid metabolism: from genetic loci to functional understanding Pedro Mata · Rodrigo Alonso · Leopoldo Pérez de Isla · Leopoldo Pérez de Isla
Evidence for more intensive cholesterol lowering Mhairi K. Doris · Marc R. Dweck · Zahi A. Fayad · Zahi A. Fayad
Macrophage-mediated mechanisms in atherosclerosis: still tangled Laurent O. Martinez · Annelise Genoux · Jean Ferrières · Thibaut Duparc · Bertrand Perret · Bertrand Perret
Fatty acid metabolism regulates cell survival in specific niches Arjen J. Cupido · Laurens F. Reeskamp · John J. P. Kastelein · John J. P. Kastelein
Clarifying complex inheritance: apolipoprotein C3 and atherosclerosis Kevin C. Maki · Mary R. Dicklin · Mary R. Dicklin
Deep thoughts on lipids and cognition Romano Regazzi · Christian Widmann · Christian Widmann
Molecular diagnosis of familial hypercholesterolaemia Mouhammad Fathallah · Richard A. Krasuski · Richard A. Krasuski
Adiponectin, lipids and atherosclerosis Colin A. Graham · Mark J. Latten · Padraig J. Hart · Padraig J. Hart
Lipoprotein(a): new insights from modern genomics Lauren Morris · Deepak Bhatnagar · Deepak Bhatnagar
Macrophage complexity in human atherosclerosis: opportunities for treatment? Graziella E. Ronsein · Jay W. Heinecke · Jay W. Heinecke
Time to ditch Hdl-c as a measure of Hdl function? Robert S. Rosenson · Robert S. Rosenson
Micrornas and lipid metabolism Michel Farnier · Michel Farnier
The onward march of PCSK9 inhibition Elena Ferrari · Esther Lutgens · Christian Weber · Christian Weber
The challenges of proprotein convertase subtilisin–kexin-9 inhibitors for lipid guidelines and models of care Lisa Juntti-Berggren · Per-Olof Berggren · Per-Olof Berggren
Genetic control of apoprotein A-I and atheroprotection: some insights from inbred strains of mice Francesca Amati · Christian Widmann · Christian Widmann
Dietary Adherence and Cardiovascular Risk Dominic S. Ng · Dominic S. Ng
Genotype-guided diagnosis in familial hypercholesterolemia: clinical management and concerns Deepak Bhatnagar · Deepak Bhatnagar
The walking dead: macrophage inflammation and death in atherosclerosis Paul N. Hopkins · Stacey R. Lane · Stacey R. Lane
Developments in intestinal cholesterol transport and triglyceride absorption Dominic S. Ng · Dominic S. Ng
Trial designs for statin muscle intolerance Anthony S. Wierzbicki · Anthony S. Wierzbicki
Novel regulators of plasma lipid levels Katia Gazzola · Laurens F. Reeskamp · Bert-Jan van den Born · Bert-Jan van den Born
Ethnicity, lipids and cardiovascular disease Binod Aryal · Abhishek K. Singh · Noemi Rotllan · Nathan L. Price · Carlos Fernández-Hernando · Carlos Fernández-Hernando
Leveraging information from genetic risk scores of coronary atherosclerosis Pari Basharat · Pari Basharat
Phenotype vs. genotype in severe familial hypercholesterolemia: what matters most for the clinician? Suleiman A. Igdoura · Suleiman A. Igdoura
Asialoglycoprotein receptors as important mediators of plasma lipids and atherosclerosis Fotios Drenos · Fotios Drenos
Mechanistic insights from combining genomics with metabolomics Bernardo L. Trigatti · Bernardo L. Trigatti
SR-B1 and PDZK1: partners in HDL regulation Iris Kindt · Pedro Mata · Joshua W. Knowles · Joshua W. Knowles
Cholesterol reduction and macrophage function: role of paraoxonases John P. Kane · Mary J. Malloy · Mary J. Malloy
The role of registries and genetic databases in familial hypercholesterolemia Mafalda Bourbon · A.C. Alves · Eric J.G. Sijbrands · Eric J.G. Sijbrands
Low-density lipoprotein receptor mutational analysis in diagnosis of familial hypercholesterolemia Themistocles L. Assimes · Elias Salfati · Liana C. Del Gobbo · Liana C. Del Gobbo
Statin-Associated immune-mediated myopathy: Biology and clinical implications Jacqueline S. Dron · Robert A. Hegele · Robert A. Hegele
Rediscovering scavenger receptor type BI: surprising new roles for the HDL receptor Natalia Loaiza · Federico Oldoni · Jan Albert Kuivenhoven · Jan Albert Kuivenhoven
Complexity of mechanisms among human proprotein convertase subtilisin–kexin type 9 variants Mary M. Kavurma · Katey J. Rayner · Denuja Karunakaran · Denuja Karunakaran
Human genetic insights into lipoproteins and risk of cardiometabolic disease Amy C. Burke · Murray W. Huff · Murray W. Huff
Impact of rare variants in autosomal dominant hypercholesterolemia causing genes Bart van de Sluis · Melinde Wijers · Joachim Herz · Joachim Herz
Mode of action of berberine on lipid metabolism: a new-old phytochemical with clinical applications? Niki Katsiki · Christos S. Mantzoros · Dimitri P. Mikhailidis · Dimitri P. Mikhailidis
HDL and the menopause Amirhossein Sahebkar · Gerald F. Watts · Gerald F. Watts
Do triglyceride-lowering drugs decrease risk of cardiovascular disease? Samar R. El Khoudary · Samar R. El Khoudary
Atherosclerosis: cell biology and lipoproteins focus on epigenetic modification and macrophage biology Dino Rotondo · Jillian Davidson · Jillian Davidson
Ins and outs of the ATP-binding cassette transporter A1 Dawn C. Schwenke · Dawn C. Schwenke
Increasing dietary fruits and vegetables to reduce healthcare costs Sabine Rütti · Christian Widmann · Christian Widmann
Are HDL receptors really located where we think they are in the liver Dominic S. Ng · Dominic S. Ng
Exploring cellular cholesterol-focused strategies in the treatment of cardiometabolic diseases Hidde Douna · Johan Kuiper · Johan Kuiper
Novel B-cell subsets in atherosclerosis Lin Deng · Angela C. Bradshaw · Andrew H. Baker · Andrew H. Baker
Role of noncoding RNA in vascular remodelling Shizuya Yamashita · Yuji Matsuzawa · Yuji Matsuzawa
Re-evaluation of cholesteryl ester transfer protein function in atherosclerosis based upon genetics and pharmacological manipulation de Vries Mr · Paul H.A. Quax · Paul H.A. Quax
Effects of melatonin on cardiovascular diseases: progress in the past year Baris Gencer · David Nanchen · David Nanchen
The multifaceted interplay between lipids and epigenetics Thomas A. Lutz · Elena Osto · Elena Osto
Diet, lipids, and cardiovascular disease Dekkers Kf · Slagboom Pe · Jukema Jw · Heijmans Bt · Heijmans Bt
Novel therapies for severe dyslipidemia originating from human genetics Daniel Gaudet · Daniel Gaudet
HDLs in crises von Eckardstein A · Rohrer L · Rohrer L
What can we learn about lipoprotein metabolism and coronary heart disease from studying rare variants Janina M. Jeff · Gina M. Peloso · Ron Do · Ron Do
Using human genetics to predict the effects and side-effects of drugs Stefan Stender · Anne Tybjærg-Hansen · Anne Tybjærg-Hansen
Metabolic syndrome: genetic insights into disease pathogenesis Maen D. Abou Ziki · Arya Mani · Arya Mani
Relation between plasma and brain lipids Cheryl L. Wellington · Ruth Frikke-Schmidt · Ruth Frikke-Schmidt
Endogenous or exogenous antioxidants vs. pro-oxidants in macrophage atherogenicity Oren Rom · Michael Aviram · Michael Aviram
Regulation of lipid metabolism by angiopoietin-like proteins Wieneke Dijk · Sander Kersten · Sander Kersten
So Much Cholesterol: the unrecognized importance of smooth muscle cells in atherosclerotic foam cell formation Joshua A. Dubland · Gordon A. Francis · Gordon A. Francis
Cholesterol-absorbed in thought Uwe J. F. Tietge · Uwe J. F. Tietge
Role of lipoprotein lipase in lipid metabolism Maryam Darabi · Anatol Kontush · Anatol Kontush
Phosphatidylserine in atherosclerosis Simon G. Pfisterer · Johan Peränen · Elina Ikonen · Elina Ikonen
Does intrauterine exposure to hypercholesterolemia adversely affect familial hypercholesterolemia phenotype Frank Schaftenaar · Vanessa Frodermann · Johan Kuiper · Esther Lutgens · Esther Lutgens
Atherosclerosis: the interplay between lipids and immune cells Zheng Wang · Debby P.Y. Koonen · Marten H. Hofker · Jingyuan Fu · Jingyuan Fu
Gut microbiome and lipid metabolism: from associations to mechanisms Bryce Chackerian · Alan T. Remaley · Alan T. Remaley
A systematic review of current studies in patients with familial hypercholesterolemia by use of national familial hypercholesterolemia registries Jeffrey W. Meeusen · Leslie J. Donato · Allan S. Jaffe · Allan S. Jaffe
Should apolipoprotein B replace LDL cholesterol as therapeutic targets are lowered Patty W. Siri-Tarino · Ronald M. Krauss · Ronald M. Krauss
Plaque angiogenesis and its relation to inflammation and atherosclerotic plaque destabilization Jan Borén · Kevin Jon Williams · Kevin Jon Williams
The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity David Y. Hui · David Y. Hui
Intestinal phospholipid and lysophospholipid metabolism in cardiometabolic disease Briot A · Bouloumié A · Iruela-Arispe Ml · Iruela-Arispe Ml
Notch, lipids, and endothelial cells Jixin Zhong · Saumya Reddy Kankanala · Sanjay Rajagopalan · Sanjay Rajagopalan
Diagnostic scoring for familial hypercholesterolaemia in practice Vinay S. Eligar · Anil Kumar Pura Narayanaswamy · Anil Kumar Pura Narayanaswamy
Bariatric surgery and remission of type 2 diabetes mellitus Abel Martin Garrido · Martin R. Bennett · Martin R. Bennett
Truths and controversies concerning the role of miRNAs in atherosclerosis and lipid metabolism Handrean Soran · See Kwok · Safwaan Adam · Jan Hoong Ho · Paul N. Durrington · Paul N. Durrington
The future of imaging in cardiovascular disease intervention trials: 2017 and beyond Richard Norman · Gerald F. Watts · William S. Weintraub · Samuel S. Gidding · Samuel S. Gidding
Challenges in the health economics of familial hypercholesterolemia Michael Davidson · Lane B. Benes · Lane B. Benes
Trojan horses for drugs: a new role for lipoproteins? Kenneth Cusi · Kenneth Cusi
Diabetes medications improve cardiovascular outcomes: the paradigm shifts Charles E. Sparks · Janet D. Sparks · Janet D. Sparks
Lipoproteins and amyloid vascular disease Maaike Kockx · Leonard Kritharides · Leonard Kritharides
Hyperlipidaemia in immunosuppression Godfrey S. Getz · Catherine A. Reardon · Catherine A. Reardon
Acetate is the master of its fate, genetics, and molecular biology bimonthly update Erik A.L. Biessen · Kristiaan Wouters · Kristiaan Wouters
Apolipoprotein CIII is a new player in diabetes Florian Kronenberg · Florian Kronenberg
Fatty acid metabolism in macrophages: a target in cardio-metabolic diseases Elias Bjornson · Martin Adiels · Marja-Riitta Taskinen · Jan Borén · Jan Borén
Kinetics of plasma triglycerides in abdominal obesity Christophe Noll · André C. Carpentier · André C. Carpentier
Dietary fatty acid metabolism in prediabetes Jennifer Taher · Sarah Farr · Khosrow Adeli · Khosrow Adeli
Inflammation, remodeling, and other factors affecting HDL cholesterol efflux Ulf Risérus · Matti Marklund · Matti Marklund
Combined hyperlipidemia: familial but not (usually) monogenic Amanda J. Brahm · Robert A. Hegele · Robert A. Hegele
Cardiovascular diseases in mega-countries: the challenges of the nutrition, physical activity and epidemiologic transitions, and the double burden of disease K. Haralambos · Pauline Annie L. Ashfield-Watt · Ian McDowell · Ian McDowell
HDL-cholesterol and apolipoproteins in relation to dementia Simón Barquera · Andrea Pedroza-Tobías · Catalina Medina · Catalina Medina
Apolipoprotein A-I interactions with insulin secretion and production Manja Koch · Majken K. Jensen · Majken K. Jensen
Clinical trials with cholesteryl ester transfer protein inhibitors Jennifer G. Robinson · Jennifer G. Robinson
Effect of inflammation on HDL structure and function Peter M. Clifton · K.M. Turner · Jennifer B. Keogh · Jennifer B. Keogh
Dairy foods and the risk of type 2 diabetes Hong Lu · Mary Sheppard · Alan Daugherty · Alan Daugherty
Calcification in atherosclerotic lesions Godfrey S. Getz · Paulette A. Krishack · Catherine A. Reardon · Catherine A. Reardon
Serum amyloid A and atherosclerosis Jillian Davidson · Dino Rotondo · Dino Rotondo
Early nutrition, epigenetics, and cardiovascular disease Laxmi Narsimha Rao Bondugulapati · Laxmi Narsimha Rao Bondugulapati
Cardiovascular polypill: time to rethink? Kang H. Zheng · Erik S.G. Stroes · Erik S.G. Stroes
HDL infusion for the management of atherosclerosis: current developments and new directions Belinda A. Di Bartolo · My Ngan Duong · Stephen J. Nicholls · Stephen J. Nicholls
The future of lipid guidelines Annefleur M. Koopen · Albert K. Groen · Max Nieuwdorp · Max Nieuwdorp
Effects of bariatric surgery on hepatic and intestinal lipoprotein particle metabolism Kerry-Anne Rye · Philip J. Barter · Blake J. Cochran · Blake J. Cochran
New oral agents for treating dyslipidemia Marie-Jeanne Bertrand · Marie-Pierre Dubé · Jean-Claude Tardif · Jean-Claude Tardif
Pharmacogenomic approaches to lipid-regulating trials Sarah Farr · Jennifer Taher · Khosrow Adeli · Khosrow Adeli
Central nervous system regulation of intestinal lipid and lipoprotein metabolism Soonkyu Chung · John S. Parks · John S. Parks
Dietary cholesterol effects on adipose tissue inflammation Nicholas Brownell · Anand Rohatgi · Anand Rohatgi
Modulating cholesterol efflux capacity to improve cardiovascular disease Tangi Smallwood · Hooman Allayee · Brian J. Bennett · Brian J. Bennett
Choline metabolites: gene by diet interactions Anne Barden · Emilie Mas · Trevor A. Mori · Trevor A. Mori
Lipoprotein(a) apheresis Satya Dash · Changting Xiao · Gary F. Lewis · Gary F. Lewis
Milk fat biomarkers and cardiometabolic disease Dick C. Chan · P. Hugh R. Barrett · Gerald F. Watts · Gerald F. Watts
n-3 Fatty acid supplementation and proresolving mediators of inflammation Sergei N. Pokrovsky · O. Afanasieva · M. Ezhov · M. Ezhov
Proprotein convertase subtilisin kexin type 9 inhibitors: update from clinical trials to real-world experience Yared Paalvast · Jan de Boer · Albert K. Groen · Albert K. Groen
High-density lipoprotein function in rheumatoid arthritis Ormseth Mj · Stein Cm · Stein Cm
The Mediterranean diet Nathan O. Stitziel · Nathan O. Stitziel
Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism Hang Sun · Aaron M. Gusdon · Shen Qu · Shen Qu
Identifying familial hypercholesterolemia in acute coronary syndrome Marleen Schonewille · Jan de Boer · Albert K. Groen · Albert K. Groen
Bile salts in control of lipid metabolism Svenja Meiler · Esther Lutgens · Christian Weber · Christian Weber
Atherosclerosis: cell biology and lipoproteins-focus on interleukin-18 signaling, chemotactic heteromers, and microRNAs Alexander J. Blood · Richard A. Krasuski · Richard A. Krasuski
Is it time to reconsider combination lipid therapy in high-risk diabetic patients? Fullerton · Fullerton
AMP-activated protein kinase and its multifaceted regulation of hepatic metabolism Daniel I. Swerdlow · David Preiss · David Preiss
Genetic insights into statin-associated diabetes risk Amirhossein Sahebkar · Gerald F. Watts · Gerald F. Watts
Developing role of microRNA-33 in lipid metabolism and atherosclerosis Marchien G. Dallinga · Geesje M. Dallinga-Thie · Geesje M. Dallinga-Thie
Role of sulfatase 2 in lipoprotein metabolism and angiogenesis Sonja C. Stadler · Ulrich Hacker · Ralph Burkhardt · Ralph Burkhardt
Cholesterol metabolism and breast cancer Aze Wilson · Cheynne McLean · Richard B. Kim · Richard B. Kim
Trimethylamine-N-oxide: a link between the gut microbiome, bile acid metabolism, and atherosclerosis Bart van de Sluis · Bart van de Sluis
In-vivo genome editing using CRISPR-Cas9 to study lipid metabolism John K. Bielicki · John K. Bielicki
ABCA1 agonist peptides for the treatment of disease Shoug M. Alashmali · Kathryn E. Hopperton · Richard P. Bazinet · Richard P. Bazinet
Lowering dietary n-6 polyunsaturated fatty acids: interaction with brain arachidonic and docosahexaenoic acids Álvaro Hernáez · Marta Farràs · Montserrat Fitó · Montserrat Fitó
Olive oil phenolic compounds and high-density lipoprotein function Dmitri Sviridov · Yury I. Miller · Yury I. Miller
Unbiased and targeted mass spectrometry for the HDL proteome Benoit J. Arsenault · Nicolas Perrot · Patrick Couture · Patrick Couture
Genetic susceptibility to cerebrovascular disease David Della-Morte · Francesca Pacifici · Tatjana Rundek · Tatjana Rundek
Relevance of lipid metabolism for brown fat visualization and quantification Maaike Schilperoort · Geerte Hoeke · Sander Kooijman · Patrick C. N. Rensen · Patrick C. N. Rensen
LDL-cholesterol transport to the endoplasmic reticulum: current concepts Martin P. Bogsrud · Stine M. Ulven · Kirsten B. Holven · Kirsten B. Holven
Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin/kexin type 9 Liv Mundal · Kjetil Retterstøl · Kjetil Retterstøl
Assessment and consequences of cell senescence in atherosclerosis Janie Allaire · Cécile Vors · Patrick Couture · Benoît Lamarche · Benoît Lamarche
The future of n-3 polyunsaturated fatty acid therapy Thibaut Quillard · Grégory Franck · Thomas Mawson · Eduardo J. Folco · Peter Libby · Peter Libby
Apolipoprotein L1 and apolipoprotein A-IV and their association with kidney function Louise Ménégaut · Charles Thomas · Laurent Lagrost · David Masson · David Masson
Central nervous system regulation of hepatic lipid and lipoprotein metabolism Graziella E. Ronsein · Tomas Vaisar · Tomas Vaisar
Recent explanatory trials of the mode of action of drug therapies on lipoprotein metabolism Sasha Singh · Masanori Aikawa · Masanori Aikawa
Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies Kenneth R. Feingold · Carl Grunfeld · Carl Grunfeld
Scavenger receptor B1 mutation, elevated HDL cholesterol and a paradoxical increase in atherosclerosis Elena Loche · Susan E. Ozanne · Susan E. Ozanne
Human microbiome as therapeutic intervention target to reduce cardiovascular disease risk Steven E. Gryn · Robert A. Hegele · Robert A. Hegele

Therapy and clinical trials
Current Opinion in Lipidology | 2018
Stephen J. Nicholls · Rishi Puri · Rishi Puri
Predicting cardiovascular disease in familial hypercholesterolemia
Current Opinion in Lipidology | 2018
Katrin Niisuke · Katalin V. Horvath · Bela F. Asztalos · Bela F. Asztalos
Where next with HDL assays
Current Opinion in Lipidology | 2018
Kamal Awad · Maciej Banach · Maciej Banach